Page last updated: 2024-11-05

ticlopidine and Embolus

ticlopidine has been researched along with Embolus in 35 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."9.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."9.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."9.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis."9.11Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005)
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."5.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation."5.17Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."5.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain."5.14Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010)
"Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis."5.11Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005)
"The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease."3.73Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006)
"Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined."2.41Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002)
" Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database."1.42Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. ( Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015)
"Embolism is a dreaded complication of infective endocarditis (IE)."1.34Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. ( Anavekar, NS; Baddour, LM; Chandrasekaran, K; Haddad, C; Khandaker, MH; Mirzoyev, Z; Steckelberg, JM; Tleyjeh, IM; Wilson, WR, 2007)
"Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition."1.33Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006)
"The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention."1.32Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003)
"A plaque embolism was excluded clinically and in the contrast-medium intensified MRT 5 days after the intervention in 79/81 (97."1.32[Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses]. ( Andresen, R; Brinckmann, W; Roth, M, 2003)
"or more) also suppressed the thrombus formation by single administration."1.29Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. ( Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A, 1995)
"Ticlopidine treatment was associated with increased platelet numbers in all 5 dogs during the heartworm-negative stage and in 4 of 5 dogs during the heartworm implantation and heartworm embolization stages."1.28Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. ( Boudreaux, MK; Dillon, AR; Ravis, WR; Sartin, EA; Spano, JS, 1991)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.86)18.7374
1990's3 (8.57)18.2507
2000's20 (57.14)29.6817
2010's11 (31.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Graham, BR1
Menon, BK1
Mahaffey, KW1
Stevens, SR1
White, HD1
Nessel, CC1
Goodman, SG1
Piccini, JP1
Patel, MR1
Becker, RC1
Halperin, JL2
Hacke, W2
Singer, DE1
Hankey, GJ1
Califf, RM1
Fox, KA1
Breithardt, G1
Amarenco, P1
Davis, S1
Jones, EF1
Cohen, AA1
Heiss, WD1
Kaste, M1
Laouénan, C1
Young, D1
Macleod, M1
Donnan, GA1
Suzuki, Y1
Suzuki, H1
Umetsu, R1
Uranishi, H1
Abe, J1
Nishibata, Y1
Sekiya, Y1
Miyamura, N1
Hara, H1
Tsuchiya, T1
Kinosada, Y1
Nakamura, M1
Blann, AD1
Skjøth, F1
Rasmussen, LH1
Larsen, TB1
Lip, GY1
Sasaki, K1
Ueno, T1
Windecker, S1
Tijssen, J1
Giustino, G1
Guimarães, AH1
Mehran, R1
Valgimigli, M1
Vranckx, P1
Welsh, RC1
Baber, U1
van Es, GA1
Wildgoose, P1
Volkl, AA1
Zazula, A1
Thomitzek, K1
Hemmrich, M1
Dangas, GD1
Connolly, SJ1
Pogue, J1
Hart, RG1
Hohnloser, SH1
Pfeffer, M1
Chrolavicius, S1
Yusuf, S1
Yamasaki, H1
Matsubara, S1
Sasaki, I1
Nagahiro, S1
Feldman, DN1
Wong, SC1
Bergman, G1
Minutello, RM1
Chua, D1
Legal, M1
Shalansky, SJ1
Gomez, CR1
Qureshi, AI1
Schwalm, JD1
Ahmad, M1
Salehian, O1
Eikelboom, JW1
Natarajan, MK1
Laufs, U1
Hoppe, UC1
Rosenkranz, S1
Kirchhof, P1
Böhm, M1
Diener, HC1
Endres, M1
Grond, M1
Meinertz, T1
Ringelstein, EB2
Röther, J1
Dichgans, M1
Naidu, SS1
Turco, MA1
Mauri, L1
Coolong, A1
Popma, JJ1
Kereiakes, DJ1
Reddy, VY1
Doshi, SK1
Sievert, H1
Buchbinder, M1
Neuzil, P1
Huber, K1
Holmes, D1
Abe, Y1
Asakura, T1
Sakamoto, N1
Ishikawa, S1
Muroi, S1
Saitoh, F1
Satoh, M1
Suzuki, S1
Ono, M1
Sakabe, A1
Iwai, M1
Sando, M1
Gotou, J1
Watanabe, Y1
Nagata, K1
Maehara, K1
Maruyama, Y1
Andresen, R1
Roth, M1
Brinckmann, W1
Massie, BM1
Krol, WF1
Ammon, SE1
Armstrong, PW1
Cleland, JG1
Collins, JF1
Ezekowitz, M1
Jafri, SM1
O'Connor, CM1
Packer, M1
Schulman, KA1
Teo, K1
Warren, S1
Markus, HS1
Droste, DW1
Kaps, M1
Larrue, V1
Lees, KR1
Siebler, M1
Patti, G1
Pasceri, V1
Nusca, A1
Di Sciascio, G1
Imray, CH1
Higman, DJ1
Marshall, C1
Cohen, SN1
Esagunde, RU1
Wong, KS1
Lee, MP1
Gan, HY1
Wong, MC1
Chang, HM1
Chen, CL1
Spengos, K1
Tsivgoulis, G1
Toulas, P1
Sameli, S1
Vassilopoulou, S1
Zakopoulos, N1
Sfagos, K1
Heiss, JM1
Sekiya, H1
Noguchi, K1
Ohashi, Y1
Kariya, Y1
Hoshino, Y1
Konishi, H1
Anavekar, NS2
Tleyjeh, IM1
Mirzoyev, Z1
Steckelberg, JM1
Haddad, C1
Khandaker, MH1
Wilson, WR1
Chandrasekaran, K1
Baddour, LM1
Henry, M1
Henry, I1
Polydorou, A2
Hugel, M1
Narita, H1
Kaburaki, M1
Doi, H1
Yasoshima, A1
Murata, S1
Bechich, S1
Arboix, A1
Kuroda, Y1
Hara, K1
Nakajima, H1
Ikari, Y1
Little, JW1
Miller, CS1
Henry, RG1
McIntosh, BA1
Boudreaux, MK1
Dillon, AR1
Sartin, EA1
Ravis, WR1
Spano, JS1
Nuttall, A1
Smith, HJ1
Loveday, BE1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248]Phase 3350 participants (Actual)Interventional2002-02-28Completed
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203]Phase 31,653 participants (Actual)Interventional2015-12-16Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]Phase 37,554 participants (Actual)Interventional2003-06-30Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
[NCT02937025]Phase 1/Phase 2154 participants (Anticipated)Interventional2017-01-31Not yet recruiting
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545]Phase 2/Phase 3800 participants (Actual)Interventional2005-02-28Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944]Phase 4400 participants (Anticipated)Interventional2015-10-13Completed
Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794]300 participants (Actual)Observational [Patient Registry]2018-03-14Completed
Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871]300 participants (Anticipated)Observational2020-07-20Not yet recruiting
CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683]Phase 31,587 participants (Anticipated)Interventional1998-10-31Completed
Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009]Phase 33,000 participants (Actual)Interventional2016-11-30Completed
Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306]Phase 2158 participants (Actual)Interventional2013-03-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Cardiovascular Death or Thromboembolic Event

Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)83
Antiplatelet68

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)148
Antiplatelet85

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)68
Antiplatelet63

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)105
Antiplatelet78

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)49
Antiplatelet30

Number of Participants With Net-clinical Benefit

The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)137
Antiplatelet100

Number of Participants With Primary Bleeding Event (PBE)

PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)46
Antiplatelet31

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)42
Antiplatelet24

Adjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA251
Placebo + ASA162

Death From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA825
Placebo + ASA841

Occurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA296
Placebo + ASA408

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Non-CNS systemic embolism- Vascular death
Clopidogrel + ASA8328428550413
Placebo + ASA92410539148380

Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death

A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years

Interventionevents per 100 pt yrs (Number)
Implantable Device2.2
Warfarin Control3.7

Procedure Success

Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure

Interventionpercentage of implant attempts (Number)
WATCHMAN90.9

The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events

Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years

InterventionEvents per 100 pt-yrs (Number)
Implantable Device3.5
Warfarin Control3.2

Anti-Drug Antibodies

"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application

InterventionParticipants (Count of Participants)
Placebo0
40 mg Revacept0
120 mg Revacept0

Any Clinical Event

patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application

InterventionNumber of Events (Number)
Placebo19
40 mg Revacept15
120 mg Revacept10

Major Bleedings

patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application

InterventionParticipants (Count of Participants)
Placebo5
40 mg Revacept6
120 mg Revacept4

New DWI Lesion(s)

The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention

InterventionNumber of new lesions (Mean)
Placebo1.2
40 mg Revacept1.0
120 mg Revacept0.6

Patients With Any Stroke or Transient Ischemic Attack (TIA)

patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application

InterventionParticipants (Count of Participants)
Placebo6
40 mg Revacept6
120 mg Revacept4

Participants With Adverse Events (AEs)

All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)

,,
Interventionparticipants (Number)
patients with adverse eventspatients with drug related AEspatients with serious AEspatients with drug related serious AEspatients with AE with fatal outcome events
120 mg Revacept3221501
40 mg Revacept41101740
Placebo3541710

Reviews

3 reviews available for ticlopidine and Embolus

ArticleYear
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug

2015
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2005, Volume: 6, Issue:9

    Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholestere

2005
Antithrombotic agents: implications in dentistry.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 93, Issue:5

    Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol

2002

Trials

9 trials available for ticlopidine and Embolus

ArticleYear
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema

2014
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
    Stroke, 2014, Volume: 45, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia;

2014
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
    Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies

2010
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
    The American journal of cardiology, 2010, Apr-15, Volume: 105, Issue:8

    Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Embolism; Female; H

2010
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
    Journal of cardiac failure, 2004, Volume: 10, Issue:2

    Topics: Adult; Aged; Anticoagulants; Aspirin; Clopidogrel; Embolism; Female; Heart Failure; Humans; Male; Mi

2004
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
    Circulation, 2005, May-03, Volume: 111, Issue:17

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism;

2005
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
    Circulation, 2005, May-03, Volume: 111, Issue:17

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism;

2005
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
    Circulation, 2005, May-03, Volume: 111, Issue:17

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism;

2005
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
    Circulation, 2005, May-03, Volume: 111, Issue:17

    Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism;

2005

Other Studies

23 other studies available for ticlopidine and Embolus

ArticleYear
Clopidogrel Load Reduces Emboli in Carotid Artery Stenosis With Free-Floating Thrombus.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2017, Volume: 44, Issue:5

    Topics: Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Embolism; Humans; Magnetic Resonance Imagin

2017
Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:5

    Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb

2015
[CHARISMA study].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Jun-20, Volume: 74 Suppl 4 Pt 1

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Embolism; Female; Humans; Male; Middle Aged; Plaque,

2016
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
    Neurologia medico-chirurgica, 2009, Volume: 49, Issue:5

    Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S

2009
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:6

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I

2009
Medical treatment of patients with intracranial atherosclerotic disease.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2009, Volume: 19 Suppl 1

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb

2009
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
    Der Nervenarzt, 2010, Volume: 81, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel;

2010
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp

2003
[Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses].
    Zentralblatt fur Chirurgie, 2003, Volume: 128, Issue:9

    Topics: Aged; Angiography; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid

2003
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
    Circulation, 2005, Nov-15, Volume: 112, Issue:20

    Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg

2005
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
    Circulation, 2005, Nov-15, Volume: 112, Issue:20

    Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg

2005
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 21, Issue:4

    Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F

2006
Spinal cord stroke in a ballet dancer.
    Journal of the neurological sciences, 2006, May-15, Volume: 244, Issue:1-2

    Topics: Accidents, Occupational; Adult; Clopidogrel; Dancing; Embolism; Female; Fibrocartilage; Humans; Inte

2006
[Emergency measures in acute arterial occlusion. Why there are still colleagues who do it incorrectly?].
    MMW Fortschritte der Medizin, 2006, Mar-23, Volume: 148, Issue:12

    Topics: Acute Disease; Angiography; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Embolism; Emergencies

2006
Saddle embolism after corrective femoral osteotomy: a case report.
    Journal of orthopaedic surgery (Hong Kong), 2006, Volume: 14, Issue:2

    Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em

2006
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, May-01, Volume: 44, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Administration Sche

2007
Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 2).
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2007, Volume: 13, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Catheterization; Clopidogrel; Embolism; Fibrinolyt

2007
Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
    Japanese journal of pharmacology, 1995, Volume: 68, Issue:4

    Topics: Administration, Oral; Animals; Antithrombins; Aspirin; Diltiazem; Dose-Response Relationship, Drug;

1995
[Significant regression of neurological hemispheric deficit].
    Neurologia (Barcelona, Spain), 1997, Volume: 12, Issue:1

    Topics: Acute Disease; Aged; Cerebral Infarction; Embolism; Female; Heart; Humans; Platelet Aggregation Inhi

1997
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
    Japanese circulation journal, 2001, Volume: 65, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang

2001
Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs.
    American journal of veterinary research, 1991, Volume: 52, Issue:12

    Topics: Adenosine Diphosphate; Animals; Blood Platelets; Collagen; Dirofilariasis; Dog Diseases; Dogs; Embol

1991
A clinically relevant model of heart failure: effects of ticlopidine.
    Cardiovascular research, 1985, Volume: 19, Issue:4

    Topics: Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Embolism; Female; Heart Failu

1985